This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Teichman, S. Search for Related Content PubMed PubMed Citation Articles by Teichman, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PYRIDOSTIGMINE BROMIDE Social Bookmarking                         What's this?

The Anticholinergic Side Effects of Disopyramide and Controlled-Release Disopyramide

Division of Cardiology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York

Until now, the potential antiarrhythmic benefits of disopyramide have been restricted by anticholinergic side effects. These side effects have included xeros tomia (dry mouth, nose or eyes), abdominal discomfort, nausea, constipation and, most importantly, urinary hesitancy and retention. A sustained-release form of pyridostigmine, an acetyl-cholinesterase inhibitor, has been shown to a) prevent the anticholinergic side effects of disopyramide when used prophylacti cally and b) to eliminate or attenuate these symptoms if they are already present. Pyridostigmine has no measurable effect on disopyramide's antiar rhythmic properties. This represents a beneficial new drug interaction which will improve tolerance of disopyramide and increase patient compliance with disopyramide-containing regimens.

Angiology, Vol. 36, No. 11, 767-771 (1985)
DOI: 10.1177/000331978503601101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?